Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Mallinckrodt
Queensland Health
Healthtrust
Cantor Fitzgerald
Citi
Federal Trade Commission
Covington

Generated: December 17, 2018

DrugPatentWatch Database Preview

BELEODAQ Drug Profile

« Back to Dashboard

When do Beleodaq patents expire, and when can generic versions of Beleodaq launch?

Beleodaq is a drug marketed by Spectrum Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the belinostat profile page.

Summary for BELEODAQ
Drug patent expirations by year for BELEODAQ
Generic Entry Opportunity Date for BELEODAQ
Generic Entry Date for BELEODAQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BELEODAQ
Synonyms for BELEODAQ
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
(E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid
(E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide
(E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide
(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-
2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-
2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-
2-Propenamide,N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-,(2E)-
414864-00-9
5OG
866323-14-0
866323-14-0 (E Isomer)
A25012
AB0007889
ABP000140
AC-25046
AKOS025401741
AN-1073
AOB87787
API0003555
AS-17068
AX8144528
BC251660
BCP9000386
BCPP000351
BDBM25150
Beleodaq (TN)
Belinostat
Belinostat (PXD101)
Belinostat - PXD101
Belinostat (PXD101)
Belinostat [USAN:INN]
Belinostat Ph3
Belinostat,PXD101, PX105684
Belinostat/PXD101,PX105684/
BRD-K17743125-001-01-9
CCG-208758
CHEBI:61076
CHEBI:94531
D0XT6W
DB05015
DTXSID60194378
E-Belinostat
EX-A180
F4H96P17NZ
GTPL7496
J-523584
KB-74881
LS41098
MFCD08064035
MLS006011091
MolPort-009-679-433
N-Hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide
N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide
N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide
N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE
N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide
N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide
N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamide
N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PR
N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE
NCNRHFGMJRPRSK-MDZDMXLPSA-N
NSC-726630
NSC726630
OR190689
PDX-101
PDX101
PubChem22405
PX 105684
PX-105684
PX105684
PX105684, 414864-00-9
PXD 101
PXD-101
PXD101
QCR-181
RL03602
RT-014445
s1085
SC-71101
SMR004702879
UNII-F4H96P17NZ
W-5363
ZINC3818726

US Patents and Regulatory Information for BELEODAQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Spectrum Pharms BELEODAQ belinostat POWDER;INTRAVENOUS 206256-001 Jul 3, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Spectrum Pharms BELEODAQ belinostat POWDER;INTRAVENOUS 206256-001 Jul 3, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Spectrum Pharms BELEODAQ belinostat POWDER;INTRAVENOUS 206256-001 Jul 3, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Spectrum Pharms BELEODAQ belinostat POWDER;INTRAVENOUS 206256-001 Jul 3, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BELEODAQ
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 500 mg/vial ➤ Subscribe ➤ Try a Free Trial

International Patents for BELEODAQ

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Mallinckrodt
Queensland Health
Healthtrust
Cantor Fitzgerald
Citi
Federal Trade Commission
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.